Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01695174 · ClinicalTrials.gov registry record · Phase 1
A Pilot Study of Xifaxan to Treat Patients With PSC
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01695174: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT01695174 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01695174, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
In the current protocol, we propose the assessment of potential beneficial effects of the antibiotic Xifaxan on liver biochemistries, liver related symptoms and Mayo risk score in 15 adult and 5 pediatric patients with PSC. Adult patients will receive Xifaxan, 550 mg twice daily over a 12-week period. Pediatric patients with PSC whose weight is greater than or equal to 40 kg will receive Xifaxan, 550 mg twice daily.
Interventions
- DRUG Xifaxan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2012-08 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01695174
The ClinicalTrials.gov registry entry for NCT01695174 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Xifaxan is the first listed.
NCT01695174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01695174 about?
NCT01695174 is a clinical study titled "A Pilot Study of Xifaxan to Treat Patients With PSC". In the current protocol, we propose the assessment of potential beneficial effects of the antibiotic Xifaxan on liver biochemistries, liver related symptoms and Mayo risk score in 15 adult and 5 pediatric patients with PSC. Adult patients will receive Xifaxan, 550 mg twice daily over a 12-week perio...
What is the current status of trial NCT01695174?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2012-08. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01695174?
The interventions under investigation include: Xifaxan (DRUG).
Who is sponsoring clinical trial NCT01695174?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.